Relationship between Ceftolozane-Tazobactam Exposure and Selection for Pseudomonas aeruginosa Resistance in a Hollow-Fiber Infection Model
暂无分享,去创建一个
Ronald N. Jones | M. Castanheira | J. McCauley | S. Bhavnani | P. Ambrose | R. Mendes | L. Friedrich | B. VanScoy | J. Steenbergen
[1] M. Bounthavong,et al. Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination , 2013, Infection and drug resistance.
[2] M. Neely,et al. Impact of Bolus Dosing versus Continuous Infusion of Piperacillin and Tazobactam on the Development of Antimicrobial Resistance in Pseudomonas aeruginosa , 2013, Antimicrobial Agents and Chemotherapy.
[3] Ronald N. Jones,et al. Relationship between Ceftolozane-Tazobactam Exposure and Drug Resistance Amplification in a Hollow-Fiber Infection Model , 2013, Antimicrobial Agents and Chemotherapy.
[4] W. Craig,et al. In Vivo Activities of Ceftolozane, a New Cephalosporin, with and without Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, Including Strains with Extended-Spectrum β-Lactamases, in the Thighs of Neutropenic Mice , 2012, Antimicrobial Agents and Chemotherapy.
[5] Ronald N. Jones,et al. Pharmacodynamics of β-Lactamase Inhibition by NXL104 in Combination with Ceftaroline: Examining Organisms with Multiple Types of β-Lactamases , 2011, Antimicrobial Agents and Chemotherapy.
[6] Ronald N. Jones,et al. Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis Strains Having Various Resistance Phenotypes , 2011, Antimicrobial Agents and Chemotherapy.
[7] G. Talbot,et al. Pharmacokinetics and Safety of CXA-101, a New Antipseudomonal Cephalosporin, in Healthy Adult Male and Female Subjects Receiving Single- and Multiple-Dose Intravenous Infusions , 2010, Antimicrobial Agents and Chemotherapy.
[8] Brian Van Scoy,et al. Impact of Different Carbapenems and Regimens of Administration on Resistance Emergence for Three Isogenic Pseudomonas aeruginosa Strains with Differing Mechanisms of Resistance , 2010, Antimicrobial Agents and Chemotherapy.
[9] Clinical,et al. Performance Standards for Antimicrobial Susceptibility Testing; Eighteenth Informational Supplement , 2008 .
[10] G. Drusano,et al. Impact of Resistance Selection and Mutant Growth Fitness on the Relative Efficacies of Streptomycin and Levofloxacin for Plague Therapy , 2007, Antimicrobial Agents and Chemotherapy.
[11] Robert Leary,et al. Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa. , 2005, The Journal of infectious diseases.
[12] Ronald N. Jones,et al. Relationships between patient- and institution-specific variables and decreased antimicrobial susceptibility of Gram-negative pathogens. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] A. Harris,et al. Risk Factors for Piperacillin-Tazobactam-Resistant Pseudomonas aeruginosa among Hospitalized Patients , 2002, Antimicrobial Agents and Chemotherapy.
[14] M. Ferraro. Performance standards for antimicrobial susceptibility testing , 2001 .
[15] Mary Jane Ferraro,et al. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .
[16] Y. Carmeli,et al. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. , 1999, Archives of internal medicine.
[17] J. Waitz. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .